By Fineline Cube 
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced a non‑exclusive licensing agreement with Pfizer (NYSE: PFE) granting the pharma giant global access to Nona’s proprietary HCAb technology platform for preclinical antibody discovery across multiple disease indications.
Agreement Overview
| Item | Detail |
|---|---|
| Licensor | Nona Biosciences |
| Licensee | Pfizer Inc. (NYSE: PFE) |
| Deal Type | Non‑exclusive licensing agreement |
| Technology | HCAb platform (fully human heavy chain antibodies) |
| Scope | Global access for preclinical antibody discovery |
| Financial Terms | Upfront payment + regulatory, clinical, and commercial milestones (undisclosed) |
| Collaboration | Nona to provide antibody discovery, development, and engineering services |
Technology Profile
- Platform: Proprietary HCAb technology generates fully human heavy chain antibodies with enhanced tissue penetration and simplified manufacturing
- B‑cell Screening: Advanced screening technology enables rapid identification of high‑affinity candidates
- Integrated Services: End‑to‑end capabilities from discovery through engineering and early development
- Strategic Value: Platform addresses industry need for novel antibody formats with improved drug‑like properties
Deal Rationale & Market Impact
- Pfizer’s Pipeline: Access to HCAb platform diversifies Pfizer’s biologics discovery toolkit, particularly for complex targets in oncology and immunology where traditional antibodies face limitations
- Nona’s Validation: Partnership with a top‑tier pharma validates Nona’s platform technology and opens door for additional licensing deals
- Financial Implications: Milestone structure provides Nona with non‑dilutive capital; upfront payment likely in the US$10‑20 million range based on comparable platform deals
- Competitive Landscape: Positions Nona alongside other antibody platform companies like Harbour BioMed and I‑Mab in the China‑US biotech partnering space
- Next Catalysts: Nona expects to announce additional partnerships in 2026, leveraging the Pfizer deal as proof‑of‑concept for its HCAb platform
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the financial terms, milestone achievements, and strategic impact of the Nona‑Pfizer agreement. Actual results may differ materially due to risks including technology validation, competitive dynamics, and Pfizer’s internal portfolio prioritization.-Fineline Info & Tech